$ALXO
ALX ONCOLOGY HOLDINGS INC

2023 Q3 Form 10-Q Financial Statement

#000095017023041319 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.510M $7.295M
YoY Change 2.89% 3.61%
% of Gross Profit
Research & Development $45.77M $29.48M
YoY Change 55.76% 10.22%
% of Gross Profit
Depreciation & Amortization $210.0K $207.0K
YoY Change 121.05% 146.43%
% of Gross Profit
Operating Expenses $53.28M $36.78M
YoY Change 45.24% 8.84%
Operating Profit -$53.28M -$36.78M
YoY Change 45.24% 8.84%
Interest Expense $391.0K $372.0K
YoY Change -71.46% -57.53%
% of Operating Profit
Other Income/Expense, Net -$1.000K $324.0K
YoY Change -88.89% -4728.57%
Pretax Income -$50.99M -$34.16M
YoY Change 44.37% 3.76%
Income Tax
% Of Pretax Income
Net Earnings -$50.99M -$34.16M
YoY Change 44.37% 3.76%
Net Earnings / Revenue
Basic Earnings Per Share -$1.24 -$0.84
Diluted Earnings Per Share -$1.24 -$0.84
COMMON SHARES
Basic Shares Outstanding 41.15M 40.87M
Diluted Shares Outstanding 41.15M 40.88M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $190.0M $212.8M
YoY Change -33.31% -32.08%
Cash & Equivalents $19.58M $38.04M
Short-Term Investments $170.4M $174.8M
Other Short-Term Assets $8.500M $6.725M
YoY Change 44.09% 93.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $199.1M $219.6M
YoY Change -31.55% -30.7%
LONG-TERM ASSETS
Property, Plant & Equipment $3.617M $3.828M
YoY Change 54.84% 134.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $6.400M $11.65M
YoY Change -22.11% 7.25%
Other Assets $10.98M $10.90M
YoY Change -32.73% -34.68%
Total Long-Term Assets $21.04M $26.37M
YoY Change -21.74% -9.6%
TOTAL ASSETS
Total Short-Term Assets $199.1M $219.6M
Total Long-Term Assets $21.04M $26.37M
Total Assets $220.1M $245.9M
YoY Change -30.72% -28.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.00M $4.115M
YoY Change 121.11% -52.59%
Accrued Expenses $21.20M $13.46M
YoY Change 11.76% -9.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $35.14M $17.57M
YoY Change 39.21% -26.64%
LONG-TERM LIABILITIES
Long-Term Debt $9.575M $9.512M
YoY Change 13488.57%
Other Long-Term Liabilities $6.638M $6.156M
YoY Change 21.07% 7.12%
Total Long-Term Liabilities $16.21M $15.67M
YoY Change 195.7% 172.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.14M $17.57M
Total Long-Term Liabilities $16.21M $15.67M
Total Liabilities $51.36M $33.24M
YoY Change 67.14% 11.92%
SHAREHOLDERS EQUITY
Retained Earnings -$440.8M -$389.8M
YoY Change 49.55% 50.25%
Common Stock $609.8M $602.8M
YoY Change 4.55% 4.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $168.8M $212.7M
YoY Change
Total Liabilities & Shareholders Equity $220.1M $245.9M
YoY Change -30.72% -28.93%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$50.99M -$34.16M
YoY Change 44.37% 3.76%
Depreciation, Depletion And Amortization $210.0K $207.0K
YoY Change 121.05% 146.43%
Cash From Operating Activities -$31.16M -$31.71M
YoY Change 0.9% 86.56%
INVESTING ACTIVITIES
Capital Expenditures -$1.300M $1.739M
YoY Change 577.08% -776.65%
Acquisitions
YoY Change
Other Investing Activities $11.51M $7.952M
YoY Change -17.12% -110.48%
Cash From Investing Activities $12.81M $6.213M
YoY Change -6.46% -108.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -110.0K 343.0K
YoY Change -19.12% -18.72%
NET CHANGE
Cash From Operating Activities -31.16M -31.71M
Cash From Investing Activities 12.81M 6.213M
Cash From Financing Activities -110.0K 343.0K
Net Change In Cash -18.46M -25.16M
YoY Change 6.56% -72.87%
FREE CASH FLOW
Cash From Operating Activities -$31.16M -$31.71M
Capital Expenditures -$1.300M $1.739M
Free Cash Flow -$29.86M -$33.45M
YoY Change -2.71% 99.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001810182
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Other Liability Current Related And Nonrelated Party Status Extensible Enumeration
OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Other Liability Current Related And Nonrelated Party Status Extensible Enumeration
OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39386
dei Entity Registrant Name
EntityRegistrantName
ALX ONCOLOGY HOLDINGS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0642577
dei Entity Address Address Line1
EntityAddressAddressLine1
323 Allerton Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
466-7125
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
ALXO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41151819
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38039000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48822000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
174797000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
217385000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6725000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4762000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
219561000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
270969000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3828000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3889000
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
11647000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
16699000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10896000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14932000
CY2023Q2 us-gaap Assets
Assets
245932000
CY2022Q4 us-gaap Assets
Assets
306489000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4115000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8073000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
260000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1650000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13197000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18602000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17572000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28325000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9512000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9389000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6156000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5311000
CY2023Q2 us-gaap Liabilities
Liabilities
33240000
CY2022Q4 us-gaap Liabilities
Liabilities
43025000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40992179
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40992179
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40861386
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40861386
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
41000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
41000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
602773000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
589735000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-312000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-845000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-389810000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-325467000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
212692000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
263464000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
245932000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
306489000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29482000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26748000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54245000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43821000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7295000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7041000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14735000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14715000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
36777000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
33789000
us-gaap Operating Expenses
OperatingExpenses
68980000
us-gaap Operating Expenses
OperatingExpenses
58536000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-36777000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-33789000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68980000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58536000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2666000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
876000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4977000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1101000
CY2023Q2 us-gaap Interest Expense
InterestExpense
372000
CY2022Q2 us-gaap Interest Expense
InterestExpense
2000
us-gaap Interest Expense
InterestExpense
759000
us-gaap Interest Expense
InterestExpense
5000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
324000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
419000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34159000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-32920000
us-gaap Net Income Loss
NetIncomeLoss
-64343000
us-gaap Net Income Loss
NetIncomeLoss
-57453000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40875457
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40875457
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40687751
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40687751
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40869021
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40869021
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40652224
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40652224
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34159000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-32920000
us-gaap Net Income Loss
NetIncomeLoss
-64343000
us-gaap Net Income Loss
NetIncomeLoss
-57453000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-224000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-650000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
533000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1256000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34383000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33570000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63810000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58709000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
263464000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6351000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
757000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30184000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
240388000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
112000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
338000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6237000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-224000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34159000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
212692000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
363049000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
185000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5501000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-606000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24533000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
343596000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
155000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
302000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5836000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-650000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-32920000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
316319000
us-gaap Profit Loss
ProfitLoss
-64343000
us-gaap Profit Loss
ProfitLoss
-57453000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
420000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
142000
alxo Operating Finance Lease Right Of Use Asset Amortization Expense
OperatingFinanceLeaseRightOfUseAssetAmortizationExpense
611000
alxo Operating Finance Lease Right Of Use Asset Amortization Expense
OperatingFinanceLeaseRightOfUseAssetAmortizationExpense
514000
us-gaap Share Based Compensation
ShareBasedCompensation
12588000
us-gaap Share Based Compensation
ShareBasedCompensation
11337000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2764000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-103000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
123000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1963000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
196000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3425000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
318000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3944000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5116000
alxo Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current
IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent
-1390000
alxo Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current
IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent
894000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1802000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2761000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-488000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-572000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59527000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37672000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
118730000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
279207000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
169667000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
20000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2429000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
846000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48508000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-260053000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
112000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
340000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
338000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
302000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
214000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
140000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
236000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
502000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-10783000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-297223000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48888000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
363667000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38105000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66444000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
75000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
266000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4684000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38039000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66378000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
66000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
66000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38105000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66444000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain amounts in the prior period have been reclassified to conform to the current period presentation.</span></p>
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
11647000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
16699000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including, but not limited to, those related to the estimated useful lives of long-lived assets, clinical trial accruals, fair value of assets and liabilities, fair value of investments and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
223494000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
274258000
CY2023Q2 us-gaap Cash
Cash
1000000
CY2022Q4 us-gaap Cash
Cash
8600000
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
211847000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
257559000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
223494000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
274258000
CY2022Q2 alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
CY2023Q2 alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
500000
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
1000000
CY2023Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
4200000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4651000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4292000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
823000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
403000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3828000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3889000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5238000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5626000
CY2023Q2 alxo Other Assets Noncurrent Other
OtherAssetsNoncurrentOther
285000
CY2022Q4 alxo Other Assets Noncurrent Other
OtherAssetsNoncurrentOther
586000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
271000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10896000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14932000
CY2023Q2 alxo Accrued Clinical And Non Clinical Costs Current
AccruedClinicalAndNonClinicalCostsCurrent
5626000
CY2022Q4 alxo Accrued Clinical And Non Clinical Costs Current
AccruedClinicalAndNonClinicalCostsCurrent
5485000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3013000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3708000
CY2023Q2 alxo Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
2537000
CY2022Q4 alxo Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
5249000
CY2023Q2 alxo Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
173000
CY2022Q4 alxo Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
2110000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1848000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2050000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13197000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18602000
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company has non-cancelable operating leases for its offices located in the U.S. As of June 30, 2023, these leases expire on various dates between 2026 and 2030.
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Certain lease agreements include one or more options to renew, with renewal terms that can extend the lease up to two years after expiration.
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
620000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
1267000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
1305000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
1187000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
912000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
2069000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7360000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1713000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5647000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
800000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4847000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5647000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y9M18D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
317000
us-gaap Operating Lease Cost
OperatingLeaseCost
635000
us-gaap Operating Lease Cost
OperatingLeaseCost
520000
CY2023Q2 alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
103000
CY2022Q2 alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
91000
alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
219000
alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
143000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
3000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
39000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
6000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
83000
CY2023Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
112000
CY2022Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
112000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
224000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
224000
CY2023Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000
CY2022Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
5000
CY2023Q2 us-gaap Lease Cost
LeaseCost
536000
CY2022Q2 us-gaap Lease Cost
LeaseCost
515000
us-gaap Lease Cost
LeaseCost
1086000
us-gaap Lease Cost
LeaseCost
975000
us-gaap Operating Lease Payments
OperatingLeasePayments
621000
us-gaap Operating Lease Payments
OperatingLeasePayments
429000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
2000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
4000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
214000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
140000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4684000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
435000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5217000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
4948000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
10600000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2023Q2 alxo Term Loan Non Current
TermLoanNonCurrent
10600000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
888000
CY2023Q2 alxo Term Loan Unamortized Final Payment
TermLoanUnamortizedFinalPayment
200000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9512000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40992179
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40861386
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12601132
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6237000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5836000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12588000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11337000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34159000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-32920000
us-gaap Net Income Loss
NetIncomeLoss
-64343000
us-gaap Net Income Loss
NetIncomeLoss
-57453000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40875457
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40875457
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40687751
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40687751
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40869021
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40869021
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40652224
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40652224
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7362950
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7362950
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5724925
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5724925
CY2023Q2 alxo Number Of Pending Or Threatened Litigation
NumberOfPendingOrThreatenedLitigation
0
CY2023Q2 us-gaap Purchase Obligation
PurchaseObligation
16511000
CY2023Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
12809000
CY2023Q2 us-gaap Purchase Obligation Due In Second And Third Year
PurchaseObligationDueInSecondAndThirdYear
3669000
CY2023Q2 us-gaap Purchase Obligation Due In Fourth And Fifth Year
PurchaseObligationDueInFourthAndFifthYear
33000
CY2023Q2 us-gaap Contractual Obligation
ContractualObligation
16511000
CY2023Q2 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
12809000
CY2023Q2 us-gaap Contractual Obligation Due In Second And Third Year
ContractualObligationDueInSecondAndThirdYear
3669000
CY2023Q2 us-gaap Contractual Obligation Due In Fourth And Fifth Year
ContractualObligationDueInFourthAndFifthYear
33000

Files In Submission

Name View Source Status
0000950170-23-041319-index-headers.html Edgar Link pending
0000950170-23-041319-index.html Edgar Link pending
0000950170-23-041319.txt Edgar Link pending
0000950170-23-041319-xbrl.zip Edgar Link pending
alxo-20230630.htm Edgar Link pending
alxo-20230630.xsd Edgar Link pending
alxo-ex10_1.htm Edgar Link pending
alxo-ex31_1.htm Edgar Link pending
alxo-ex31_2.htm Edgar Link pending
alxo-ex32_1.htm Edgar Link pending
alxo-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
alxo-20230630_def.xml Edgar Link unprocessable
alxo-20230630_lab.xml Edgar Link unprocessable
alxo-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
alxo-20230630_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
alxo-20230630_cal.xml Edgar Link unprocessable